Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Net Margin (2016 - 2026)

Dexcom has reported Net Margin over the past 17 years, most recently at 16.74% for Q1 2026.

  • Quarterly Net Margin rose 656.0% to 16.74% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 19.31% through Mar 2026, up 641.0% year-over-year, with the annual reading at 17.94% for FY2025, 365.0% up from the prior year.
  • Net Margin was 16.74% for Q1 2026 at Dexcom, down from 21.22% in the prior quarter.
  • Over five years, Net Margin peaked at 24.78% in Q4 2023 and troughed at 6.55% in Q1 2023.
  • The 5-year median for Net Margin is 13.62% (2024), against an average of 14.63%.
  • Year-over-year, Net Margin surged 1351bps in 2023 and then crashed -1115bps in 2024.
  • A 5-year view of Net Margin shows it stood at 11.26% in 2022, then skyrocketed by 120bps to 24.78% in 2023, then plummeted by -45bps to 13.62% in 2024, then skyrocketed by 56bps to 21.22% in 2025, then dropped by -21bps to 16.74% in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Net Margin are 16.74% (Q1 2026), 21.22% (Q4 2025), and 23.47% (Q3 2025).